Silo pharma successfully completes first phase of dose-ranging study of spc-15 an intranasal treatment for ptsd

Final validation report expected in first quarter 2024 englewood cliffs, nj, jan. 04, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or “the company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today provided an update on its previously announced dose-ranging study of spc-15, a targeted prophylactic treatment for post-traumatic stress disorder (ptsd). the purpose of the study is to identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small animals to determine the therapeutically relevant dose range with the goal of bringing us closer to human trials.
SILO Ratings Summary
SILO Quant Ranking